AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Koselugo (selumetinib) — Europe YoY CER by Quarter
Koselugo (selumetinib) — Europe YoY CER (%) (%)
AstraZeneca Koselugo (selumetinib) — Europe YoY CER: 27.0% in Q2 2026, down 10.0 pts from a year earlier.
Latest, Q2 2026
27.0%
Period ended Jun 30, 2026
Change on a year earlier
-10.0 pts
37.0% in Q2 2025
History
12 quarters
Since Q4 2020
Sources
12
Documents cited below
Where the Q2 2026 figure comes from
“|| Koselugo | 177 | | 29 | | 27 | | 52 | | - | | 54 | | 51 | | 45 | | 50 | | 34 | | 27 | | 21 | | 78 | | 90”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Koselugo (selumetinib) — Europe YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 27.0% | -10.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 28.0% | -62.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 46.0% | -44.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 44.0% | -50.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 37.0% | – | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 90.0% | +21.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 90.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 94.0% | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 69.0% | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | 0.0% | – | Form 6-K FY2021Q2 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | 0.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | 0.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Koselugo (selumetinib) — Europe YoY CER (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-koselugo-eu-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.